Craneware (LON:CRW) Sets New 52-Week High at $2,278.00

Craneware plc (LON:CRW)’s share price reached a new 52-week high during trading on Wednesday . The stock traded as high as GBX 2,278 ($28.14) and last traded at GBX 2,275 ($28.10), with a volume of 50163 shares changing hands. The stock had previously closed at GBX 2,230 ($27.54).

Wall Street Analysts Forecast Growth

Separately, Berenberg Bank upped their target price on Craneware from GBX 2,300 ($28.41) to GBX 2,600 ($32.11) and gave the company a “buy” rating in a research note on Monday, March 4th.

Craneware Price Performance

The stock has a market capitalization of £791.84 million, a price-to-earnings ratio of 10,666.67 and a beta of 0.14. The company has a quick ratio of 1.00, a current ratio of 0.78 and a debt-to-equity ratio of 19.15. The company has a 50 day moving average of GBX 2,178.99 and a 200 day moving average of GBX 1,903.64.

Craneware Cuts Dividend

The company also recently declared a dividend, which was paid on Monday, April 15th. Shareholders of record on Thursday, March 21st were paid a dividend of GBX 13 ($0.16) per share. The ex-dividend date of this dividend was Thursday, March 21st. This represents a yield of 0.62%. Craneware’s dividend payout ratio is presently 13,809.52%.

Craneware Company Profile

Craneware plc, together with its subsidiaries, develops, licenses, and supports computer software for the healthcare industry in the United States. The company provides solutions, such as Trisus pricing transparency software; Trisus Pricing Analyzer, a solution that simplifies and automates the price modeling process; Trisus Chargemaster, an automated chargemaster management solution; InSight Medical Necessity, a solution that offers medical necessity for the United States payors; Trisus Claims Informatics, a retrospective charge capture analytical application that identifies areas of risk for its team to investigate; Trisus Supply, a solution that improves supplies reimbursement; and InSight Audit, an audit management solution for government and commercial payors.